AllDocs -> cancers

Gastrointestinal Lymphoma Protocol applies to Hodgkin and non-Hodgkin lymphomas of the gastrointestinal tract. Protocol revision date: January 2004 No AJCC/UICC TNM staging system Procedures • Cytology (No Accompanying Checklist) • Incisional Biopsy (No Accompanying Checklist) • Resection Author Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada For the Members of the Cancer Committee, College of American Pathologists Previous contributor: Leslie H. Sobin, MD Page 2 Gastrointestinal Lymphoma • Hematologic System CAP Approved 2 © 2004. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols ...

Non-Hodgkin Lymphoma Protocol applies to non-Hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2004 No AJCC/UICC staging system Procedures • Cytology (No Accompanying Checklist) • Biopsy • Resection of Lymph Node or Other Organ Authors Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada Jonathan Said, MD Department of Pathology, UCLA School of Medicine, Los Angeles, California For the Members of the Cancer Committee, College of American Pathologists Previous contributors: Nancy L. Harris, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Judith Ferry, MD; Claire Fung, MD; Irene Kuter, MD; Peter Mauch, MD Page 2 Non-Hodgkin Lymphoma • Hematologic System CAP Approved 2 © 2004. ...

lymphoma Gastrointestinal Lymphoma Protocol applies to Hodgkin and non-Hodgkin lymphomas of the gastrointestinal tract. Protocol revision date: January 2004 No AJCC/UICC TNM staging system Procedures ? Cytology (No Accompanying Checklist) ? Incisional Biopsy (No Accompanying Checklist) ? Resection Author Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada For the Members of the Cancer Committee, College of American Pathologists Previous contributor: Leslie H. Sobin, MD © 2004. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical ...

Hodgkin Lymphoma Protocol applies to Hodgkin lymphoma involving any organ system except for the gastrointestinal tract. Protocol revision date: January 2004 No AJCC/UICC staging system Procedures • Cytology (No Accompanying Checklist) • Biopsy • Staging Procedure Authors Jonathan Said, MD Department of Pathology, UCLA School of Medicine, Los Angeles, California Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada For the Members of the Cancer Committee, College of American Pathologists Previous contributors: Judith A. Ferry, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Claire Fung, MD; Nancy L. Harris, MD; Irene Kuter, MD; Peter Mauch, MD Page 2 Hodgkin Lymphoma • Hematologic System CAP Approved 2 © 2004. College of American Pathologists. ...

Poorly Differentiated Carcinoma Image 10: Synaptophysin (A) and Epithelial markers (B) will be positive in most small cell undifferentiated carcinoma, while LCA (Image 6 ) will be negative in carcinomas. Synaptopysin and AE1/AE3 keratin stain x50. A A B B Page 2 Differential diagnosis Melanoma Melanoma can mimic any neoplasm, and should be part of the differential diagnosis of any neoplasm with a single cell pattern. The epithelioid variant of melanoma usually has cells 2 to 3 times the size of large cell lymphoma , has prominent nucleoli and are often binucleate. Helpful immunologic stains include HMB45 as well as melan A. Page 3 Melanoma Image 11: Romanowsky Stained smear, 50x. Notice how large the cells are and their abundant cytoplasm. The nuclei are several times larger than ...

GUIDELINES FOR THE MANAGEMENT OF MALIGNANT LYMPHOMA PUBLIC MEETING Date: MONDAY 15 MARCH 2004 VENUE: STAMFORD AIRPORT HOTEL, SYDNEY AIRPORT TIME: 1000 TO 1600 Kindly supported by INTERNATIONAL GUEST SPEAKERS Dr Michael Pfreundschuh is Professor and Director of the Department of Internal Medicine at the University of Saarland, Homburg, Germany. He is also the lead investigator of the German High Grade non-Hodgkin’s lymphoma study group. Dr Andrew Lister is Professor and Director of the Department of Medical Oncology, St. Bartholomew’s Hospital, London. U.K. His is a major contributor to U.K. Lymphoma and Leukaemia Studies. TOPICS FOR THE DAY WILL INCLUDE Diagnostic Pathology, Hodgkin Lymphoma , Indolent and Aggressive Lymphomas, Extranodal Disease, Complication of Treatment, Consumer Issues REGISTRATION FORM – All attendees must complete ...

lymphoma CUTANEOUS T-CELL LYMPHOMA BACKGROUND Cutaneous T-Cell Lymphomas (CTCL) is the most common form of T-cell lymphoma in adults. CTCL is considered a form of extranodal, indolent T-cell Non-Hodgkin?s Lymphoma Encompasses several discrete diseases with the common characteristic of lymphomatous involvement of the skin CTCL can be subdivided into the following: Mycosis Fungoides, Sezary Syndrome, Large cell cutaneous T-cell lymphoma Mycosis Fungoides and Sezary Syndrome involves aberrant CD4+ helper T-cells DEFINITION Mycosis Fungoides(MF): CD4+ T-cell lymphoma confined to the skin. Sezary Syndrome: erythrodermic, leukemic variant of Mycosis Fungoides. Original description of syndrome included the following: Generalized erythroderma Lymphadenopathy Atypical T-cells (Sezary cells) in the peripheral blood (>1000/ µ L Sezary cells ...

RIMARY epidural lymphomas comprise only 7% of all intracranial lymphomas and must be distin- guished from meningeal infiltration by the presence of a systemic lymphoproliferative disorder. Found pre- dominately in elderly men, primary epidural lymphomas are often classified as low- or intermediate-grade lesions, and they are largely composed of centrocytic and centro- blastic cells. Diagnosis is based on the absence of other primary or systemic lymphomas, and differential diag- noses include meningioma and meningeal infiltration by other primary or metastatic tumors. We report a case of primary epidural lymphoma in a 70- year-old man. The immunohistochemical and molecular features of the tumor indicated centrofollicular differenti- ation. Case Report Presentation. This 70-year-old man reported increasing difficulty walking. Symptoms had begun 1 month earlier with paresthesias ...

New Finding Will Improve Lymphoma , Autoimmune Disorder Treatments DURHAM, N.C. -- Duke University Medical Center immunologists have pinpointed how a widely used treatment for non Hodgkin's lymphoma attacks abnormal immune cells, called B cells. They believe that their discovery in mice of how the antibody rituximab kills B cells will lead to improved treatments. Such improvement is critically important, since the drug is currently effective in only about half of lymphoma patients, and virtually all patients experience eventual relapse and cease responding to the drug. The drug also has similar drawbacks in its use as a treatment for autoimmune diseases such as rheumatoid arthritis, in which abnormal B cells attack the body's own tissues. Led by Thomas Tedder, Ph. D., professor and chair of immunology, the researchers published their findings June 21, 2004, in the advanced online version of the Journal of Experimental Medicine. ...

Southwest Oncology Group Clinical Research Associate Manual CHAPTER 11 LYMPHOMA Page 2 Southwest Oncology Group Clinical Research Associate Manual 11-2 L YMPHOMA J UNE 2000 Disease Information The two main malignant diseases of the lymphoreticular system are non-Hodgkin's lymphoma and Hodgkin's disease. Lymphoma is a general term applied to a heterogeneous group of cancers which develop from lymphoreticular tissue. The lymphoreticular system is part of the immune system. The lymphocyte is the principal cellular component of lymphoid tissue. There are two major populations of lymphoreticulum cells, T-cells (lymphocytes processed through the thymus) and B-cells (thymus independent cells). Other cells of the lymphoreticular system include cells of the monocyte macrophage series, reticulum supporting cells and ...

Bangkok, Thailand October 24–28, 1999 71 Therapy of Aggressive Lymphoma James O. Armitage In much of the world, non-Hodgkin’s lymphomas are in- creasing in frequency. In the United States, approximately 60,000 cases will be diagnosed this year. The explanation for the rising incidence of non-Hodgkin’s lymphoma is not known. However, there have been numerous advances in our understanding of the biology of the disorder, our ability to classify them as specific diseases, and our knowledge about their management. Classification of non-Hodgkin’s Lymphoma Unlike the related disorder Hodgkin’s disease, non- Hodgkin’s lymphoma has a firmly established cellular ori- gin with morphologic subtypes corresponding to various stages of lymphocyte differentiation. The specific diagno- sis should be based on the evaluation of an adequate biopsy specimen by an experienced ...

Patients Against Lymphoma Patients helping Patients 1305 Mason Avenue Staten Island, NY 10306 Phone: 718-980-0635 | Fax: 801-409-5736 KarlS@Lymphomation.org www.Lymphomation.org W e are guided by our scientific advisors, the peer-reviewed literature, medical professionals fighting lymphoma , and patient questions . We continuously improve our website in response to visitor questions and patient needs . by linking you directly to reputable sources of information, such as ClinicalTrials.gov. Visit us at www.Lymphomation.org What’s Lymphoma ? L ymphoma is a cancer that affects blood cells called lymphocytes – immune cells that normally protect you from illness. Damage to genes in these cells can sometimes lead to abnormal cell behavior ...

lymphoma B-Cell Lineage NHL: REAL Classification I. Indolent (Low Risk) CLL/SLL; LPL/Waldenström’s macroglobulinemia; MZL; follicle center cell, follicular II. Aggressive (Intermediate Risk) MCL; follicular large cell; diffuse large B cell; primary mediastinal large B cell III. Very Aggressive (High Risk) Precursor B-lymphoblastic; Burkitt’s Harris et al. Blood. 1994;84:1361-1392. Chromosomal Translocations: Mechanism of Oncogene Activation in B-Cell Malignancies Courtesy of John C. Reed, MD, PhD. Trans- Oncogene location Protein Function Disease bcl-1 t(11;14) Cyclin D1 Cell cycle MCL bcl-2 t(14;18) Bcl-2 (antiapoptosis) Apoptosis NHL bcl-3 t(14;19) Rel/NF- k B inhibitor&...

Bangkok, Thailand October 24–28, 1999 10 P LENARY S ESSIONS Transplantation in Lymphoma James O. Armitage Since its inception, bone marrow transplantation has been an obvious treatment to test for patients with lymphoma . Lymphoma is a chemotherapy-sensitive malignancy in which escalating the doses of treatment might be expected to in- crease the cure rate. However, the first cure of lymphoma using high-dose therapy and autologous bone marrow trans- plantation was not reported until 1978. 1 Over the ensuing decade, many of the problems involved in autologous trans- plantation for patients with lymphoma were resolved, and high-dose therapy and hematopoietic stem cell transplanta- tion using either bone marrow or blood derived cells has become a common treatment. Allogeneic bone marrow transplantation ...

266 Experimental Oncology 25, 266-269, 2003 (December) Design of new antitumor drugs of low toxicity and high specific activity is extremely important problem. Im- idazolyl group is pharmacologically active and it is present in the structure of several drugs used in clinical oncolo- gy. Three new compounds containing mentioned group were synthesized recently. In three murine tumor cell lines (MG-22A ? hepatoma, B-16 ? melanoma, Neuro2A ? neuroblastoma) two of these compounds [3-(imidazolyl-1)-propyl-amide-4,5,5?trimethyl-pyrro- lin-2-one (IPATP) and 3-(imidazolyl-1)- propyl)-4- methyl-1-oxaspiro(4,5)-deca-3-en-2-one (IPMOSD)] revealed in vitro antitumor activity [1, 2]. However, the genotoxic activity of these compounds is not known. According to EPA (U.S. Environmental Protection Agency) and UKCOM (United Kingdom Committee on Mutagenicity of Chemicals in Food, Consumer Products and ...

In November 2001, the Cure For Lymphoma Foundation and the Lymphoma Research Foundation of America merged to become the Lymphoma Research Foundation (LRF), the nation’s foremost organization devoted to furthering lymphoma research and serving the needs of those affected by this disease. We know that you share in our excitement about the many opportunities this merger has created to strengthen our fight against lymphoma . Through this merger, LRF has emerged with a strong, unified voice to make the needs of those affected by lymphoma a national pri- ority. LRF will seek an expansion of federal funding of lymphoma research to identify new treatments, advocate for acceleration of the approval process of novel therapeutics and work to insure that lymphoma patients have access to the highest quality medical care. The LRF has established a Scientific Advisory Board (SAB) ...

Introduction The overall incidence of non-Hodgkin’s lym- phoma (NHL) has been rising during the past few decades. 1,2 According to the National Cancer Insti- tute,the incidence per 100,000 persons climbed from 8.5 in 1973 to 13.7 in 1987 — an increase of more than 50%. 3 The increase has been largely confined to two age groups:men 24 to 54 years of age and individ- uals = 65 years of age. 2 In fact, data from the Veterans Affairs medical system have shown that approximate- ly half of all NHLs now occur in individuals = 60 years of age. 4 Whereas the increase in NHLs among younger men is likely the result of the spread of the acquired immunodeficiency syndrome (AIDS), 5 reasons for the increase among older persons remain unclear. Cancer Control 5 Non-Hodgkin’s Lymphoma in the Elderly ...